Neoadjuvant, @entity5948 -free chemotherapy with @entity3003 and XXXX in triple-negative, @entity0 : a multicentric analysis of rates of pathologic complete response and survival.

@entity1 @entity137 @entity0 @entity8253 @entity5948 @entity3003 @entity3907 @entity1205
INTRODUCTION: @entity0 ( @entity0 ) has the highest mortality rates of all subtypes. @entity5948 and @entity3907 regimens yield unsatisfactorily low rates of pathologic complete response (pCR) and are often not feasible in cardiac comorbidity. This study seeks to increase pCR and survival by introducing platin agents. @entity1 AND METHODS: In this multicentric, open-label study with six cycles of @entity1205 (75mg/m(2)) and @entity3003 AUC 6 q3w, @entity1 were unwilling or unsuitable for @entity5948 -based regimens. Primary endpoint was pCR (ypT0/ypTis ypN0) and survival. RESULTS: pCR rate was 50%. After 2 and 5years, overall survival (OS) was 96.7 and 89.7%, disease-free-survival (DFS) 96.7 and 85.7%, DDFS 96.7 and 89.6%. Grade 3/4 @entity137 were rare. Ninety-three per cent of @entity1 completed six cycles. No @entity137 -related treatment discontinuation or febrile neutropaenia was recorded. CONCLUSION: This regimen is highly effective and feasible in @entity0 and may be combined with @entity8253 .
